marketshareAI
Theme

Hikma Pharmaceuticals

HIKHealthcare
1,562.00GBX
-0.32%
Market Cap
3.46B
Volume
257.53k
34% of avg
P/E Ratio
883.10
EPS (TTM)
1.77
Beta
0.73
Day Range
1,555.00p - 1,571.84p
52 Week Range
1,482.00p1,562.00p2,360.00p
1,562.00p

Upcoming Events

Late 2027
Bedford manufacturing facility fully operational
High Impact Event
2028
Revenues from Bedford facility expected to accelerate
High Impact Event
January 2030
Group revenue target of $5 billion
High Impact Event
HIK
NEUTRAL

Hikma Pharmaceuticals Director Increases Shareholding

The Executive Vice Chairman of the pharmaceutical company has purchased 100,000 shares.

HIK
NEUTRAL

Hikma Pharmaceuticals Announces Director/PDMR Shareholding Transactions

The pharmaceutical company has announced changes to the shareholding positions of its executive directors and a non-executive director.

HIK
NEUTRAL

Hikma Pharmaceuticals Announces Director/PDMR Shareholding Changes

The pharmaceutical company has announced changes in shareholdings by its executive directors and a non-executive director.

HIK
NEUTRAL

Hikma Pharmaceuticals Announces CEO Change and Board Appointment

The pharmaceutical company has announced the departure of its CEO and the appointment of a new CFO to the Board of Directors.

HIK
NEUTRAL

Hikma Pharmaceuticals Announces Major Shareholder Disclosure

The pharmaceutical company has received a notification from a major shareholder regarding a change in their shareholding position.

HIK
NEUTRAL

Hikma Pharmaceuticals Director Increases Stake

The executive chairman of the pharmaceutical company has purchased additional shares in the business.

HIK
NEUTRAL

Hikma Pharmaceuticals Announces Director/PDMR Shareholding Changes

The pharmaceutical company has announced changes to the shareholdings of its executive vice chairman and senior independent director.

HIK
NEUTRAL

Hikma Pharmaceuticals Confirms 2025 Guidance, Updates Medium-Term Outlook

The pharmaceutical company confirms 2025 guidance but adjusts medium-term outlook, citing supply chain issues and manufacturing delays.

HIK
NEUTRAL

Hikma Pharmaceuticals Directors Increase Shareholdings

The pharmaceutical company's directors have increased their shareholdings through a dividend reinvestment plan.

HIK
NEUTRAL

Hikma Pharmaceuticals Announces Director Share Purchase

The pharmaceutical company has announced a director has purchased shares in the business.